Author

V. C. Soares

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Q. Sacramento· 3 shared J. R. Temerozo· 3 shared N. Fintelman-Rodrigues· 3 shared P. T. Bozza· 3 shared T. M. L. Souza· 3 shared A. C. Ferreira· 2 shared D. C. Bou-Habib· 2 shared M. Mattos· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

C. Q. Sacramento

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.

C. Q. Sacramento, N. Fintelman-Rodrigues, S. S. G. Dias, J. R. Temerozo, A. d. P. D. Da Silva, C. S. da Silva, A. C. Ferreira, M. Mattos, V. C. Soares, F. Pereira-Dutra, M. D. Miranda, D. F. Barreto-Vieira, M. A. N. da Silva, S. de Siqueira Santos, M. Torres, , T. M. L. Souza

This paper shows mefloquine inhibits SARS-CoV-2 infection in relevant cells more effectively than chloroquine without promoting viral mutations.

bioRxiv · Jul 21, 2021Microbiology

Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility

J. A. Salerno, T. Torquato, J. R. Temerozo, L. Goto-Silva, M. A. Mendes, C. Q. Sacramento, N. Fintelman-Rodrigues, G. Vitoria, L. R. Q. Souza, I. M. Ornelas, C. Verissimo, K. Karmirian, C. d. S. G. Pedrosa, S. d. S. G. Dias, V. C. Soares, , S. Rehen

This study shows that inhibiting the Sigma-1 receptor with NE-100 reduces SARS-CoV-2 infection in human cardiomyocytes but also impairs cytoskeleton and contractility.

bioRxiv · Feb 20, 2021 · PreprintCell Biology

VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells.

J. R. Temerozo, C. Q. Sacramento, N. Fintelman-Rodrigues, C. R. R. Pao, C. S. de Freitas, S. d. S. G. Dias, A. C. Ferreira, M. Mattos, V. C. Soares, L. Teixeira, I. G. de Azevedo-Quintanilha, E. D. Hottz, P. Kurtz, F. A. Bozza, P. T. Bozza, , D. C. Bou-Habib

The paper shows elevated VIP plasma levels in severe COVID-19 patients correlate with survival and protective effects against SARS-CoV-2 in vitro.

bioRxiv · Jul 25, 2020Immunology